[go: up one dir, main page]

AR119021A1 - Composiciones de acetato de leuprolida y métodos de uso de estas para tratar el cáncer de mama - Google Patents

Composiciones de acetato de leuprolida y métodos de uso de estas para tratar el cáncer de mama

Info

Publication number
AR119021A1
AR119021A1 ARP200101496A ARP200101496A AR119021A1 AR 119021 A1 AR119021 A1 AR 119021A1 AR P200101496 A ARP200101496 A AR P200101496A AR P200101496 A ARP200101496 A AR P200101496A AR 119021 A1 AR119021 A1 AR 119021A1
Authority
AR
Argentina
Prior art keywords
sustained release
release composition
biodegradable polymer
breast cancer
methods
Prior art date
Application number
ARP200101496A
Other languages
English (en)
Inventor
John Middleton
Avinash Nangia
John Arthur Mlane
Terri L Morton
Original Assignee
Tolmar International Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tolmar International Ltd filed Critical Tolmar International Ltd
Publication of AR119021A1 publication Critical patent/AR119021A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Composiciones y métodos para la supresión de la función ovárica en sujetos con cáncer de mama receptor hormonal positivo. Reivindicación 1: Un producto, que comprende una composición de liberación prolongada caracterizado porque comprende: a) un solvente orgánico; b) leuprolida o una sal de aceptable desde el punto de vista farmacéutico de esta, en donde una cantidad de equivalente de base libre de leuprolida es de alrededor de 26 mg a alrededor de 30 mg; y c) un polímero biodegradable que comprende segmentos de copolímero de poli(lactida-o-glicólido) (PLG), en donde la relación molar de la lactida con respecto a los monómeros de glicólido es de 70:30 a 80:20, en donde el polímero biodegradable no tiene sustancialmente grupos ácido carboxílico titulables y en donde al menos un grupo terminal distal del polímero biodegradable está terminado en hidroxilo, en donde: la composición de liberación prolongada está formulada para su administración subcutánea, tras el contacto de la composición de liberación prolongada con un fluido corporal, el solvente orgánico se disipa y se forma un depósito sólido o semisólido in situ, la composición de liberación prolongada tiene la capacidad de suprimir el nivel de estradiol (E2) de un sujeto a menos de 20 pg/ml durante un período de tiempo de tres meses.
ARP200101496A 2019-05-27 2020-05-27 Composiciones de acetato de leuprolida y métodos de uso de estas para tratar el cáncer de mama AR119021A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962853153P 2019-05-27 2019-05-27

Publications (1)

Publication Number Publication Date
AR119021A1 true AR119021A1 (es) 2021-11-17

Family

ID=70922081

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP200101496A AR119021A1 (es) 2019-05-27 2020-05-27 Composiciones de acetato de leuprolida y métodos de uso de estas para tratar el cáncer de mama

Country Status (17)

Country Link
US (1) US20220265760A1 (es)
EP (1) EP3975990A1 (es)
JP (1) JP2022535694A (es)
KR (1) KR20220041782A (es)
CN (1) CN114144169A (es)
AR (1) AR119021A1 (es)
AU (1) AU2020284587A1 (es)
BR (1) BR112021023904A2 (es)
CA (1) CA3141456A1 (es)
EA (1) EA202193257A1 (es)
IL (1) IL288503A (es)
MX (1) MX2021014540A (es)
PH (1) PH12021552976A1 (es)
SG (1) SG11202112888RA (es)
TW (1) TWI757753B (es)
UY (1) UY38717A (es)
WO (1) WO2020240417A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4135830T3 (pl) 2020-12-23 2025-01-07 Tolmar International Limited Układy dla zespołów zaworów strzykawek mieszających i sposoby
USD1029245S1 (en) 2022-06-22 2024-05-28 Tolmar International Limited Syringe connector

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
BR9507313A (pt) 1994-04-08 1997-10-07 Atrix Lab Inc Composição liquida de liberação adequada para a formação de um implante de liberação controlada sistema polimérico curativo filmico microporoso biodegradável precursor de implante de liberação controlada para a implantação em um indivíduo polímero termoplástico solvente orgánico composicão de pré-polimero liquido componente de liberação controlada agente ativo uso da composição liquida de liberação e processos para forma um implante microporoso de liberação prolongada e para liberar um agente ativo em um individuo
US6565874B1 (en) 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
KR20150017777A (ko) * 2006-01-18 2015-02-17 포시에이서 파마슈티컬스 인코포레이티드 안정성이 강화된 약학 조성물
HRP20231117T3 (hr) * 2007-02-15 2023-12-22 Tolmar International Limited Poli-(laktid-ko-glikolid) sa smanjenim efektom naglog oslobađanja
PL4241849T3 (pl) * 2011-10-14 2025-01-13 F. Hoffmann-La Roche Ag Zastosowania i wyrób przemysłowy zawierający pertuzumab, inhibitor dimeryzacji HER2

Also Published As

Publication number Publication date
TWI757753B (zh) 2022-03-11
EP3975990A1 (en) 2022-04-06
US20220265760A1 (en) 2022-08-25
CN114144169A (zh) 2022-03-04
WO2020240417A1 (en) 2020-12-03
TW202110472A (zh) 2021-03-16
AU2020284587A1 (en) 2022-01-06
CA3141456A1 (en) 2020-12-03
UY38717A (es) 2020-11-30
IL288503A (en) 2022-01-01
EA202193257A1 (ru) 2022-03-10
KR20220041782A (ko) 2022-04-01
JP2022535694A (ja) 2022-08-10
MX2021014540A (es) 2022-04-12
BR112021023904A2 (pt) 2022-02-01
PH12021552976A1 (en) 2022-07-04
SG11202112888RA (en) 2021-12-30

Similar Documents

Publication Publication Date Title
AU2020250230B2 (en) Compositions of a polyorthoester and an aprotic solvent
US10646572B2 (en) Pharmaceutical compositions with enhanced stability
US20210154301A1 (en) Biodegradable drug delivery compositions
Kim et al. Poly (d, l-lactide-co-glycolide) nanoparticles as delivery platforms for TLR7/8 agonist-based cancer vaccine
CA2731316C (en) Pharmaceutical compositions
AR119021A1 (es) Composiciones de acetato de leuprolida y métodos de uso de estas para tratar el cáncer de mama
BRPI0514297A (pt) composições farmacêuticas para liberação controlada de compostos biologicamente ativos
CA2567827C (en) Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons
JP7138626B2 (ja) アルキルアンモニウムｅｄｔａ塩を含む混合物及び製剤
RU2011105029A (ru) Доставка октреотида из сухих лекарственных форм
MX2012010691A (es) Composiciones farmaceuticas de ligandos receptores de secretagoga de la hormona de crecimiento.
RU2017110076A (ru) Фармацевтическая композиция и способы
AU2005328680C1 (en) Pharmaceutical compositions and methods for peptide treatment
US9364518B2 (en) Pharmaceutical composition containing goserelin for in-situ implant
MX2022000489A (es) Formulacion de larga duracion que contiene rivastigmina y metodo para prepararla.
AR098389A1 (es) Complejos de fulvestrant y sus derivados, proceso para su preparación y composiciones farmacéuticas que los contienen
SE9603480D0 (sv) Beredningsform för svårlösliga läkemedel
KR20210005542A (ko) 선택된 방출 기간을 갖는 약제학적 조성물
JP2022541452A (ja) がんの治療のための方法および組成物
WO2004091541A3 (en) Methods for the controlled delivery of pharmacologically active compounds
Yang et al. Molecular design of hyaluronic acid hydrogel networks for long-term controlled delivery of human growth hormone
Masoumzadeh et al. Development of polymeric micelles loaded with STAT3 inhibitory, stattic, for cancer treatment
JP2023553674A (ja) 医薬組成物
WO2023044491A1 (en) Lipiodol formulation for transarterial chemoimmunoembolization
TW200831131A (en) Pharmaceutical compositions with enhanced stability